drugset / Trial / NCT01586624
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether using two drugs together called vandetanib and selumetinib is effective in the treatment of cancer. The first part of this study will include patients with any solid tumour and the second part of this study will include only patients with non small cell lung cancer. The four main aims of this clinical study are to find out: * If the two drugs can be given safely to patients when given together. * The maximum dose that can be given safely to patients. * More about the potential side effects of the drugs and how they can be managed. * What happens to vandetanib and selumetinib inside the body.
Timeline
- Start
- 2012-01-10
- Primary completion
- 2020-06-11
- Completion
- 2020-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selumetinib | Small molecule | 25 mg | Oral |
| Subject | Selumetinib | Small molecule | 50 mg | Oral |
| Subject | Selumetinib | Small molecule | 75 mg | Oral |
| Subject | Selumetinib | Small molecule | 100 mg | Oral |
| Subject | Selumetinib | Small molecule | 125 mg | Oral |
| Subject | Vandetanib | Small molecule | 100 mg | Oral |
| Subject | Vandetanib | Small molecule | 200 mg | Oral |
| Subject | Vandetanib | Small molecule | 300 mg | Oral |